PharmiWeb Recruiter Blog


Roche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease

  • Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel
  • The Elecsys Amyloid Plasma Panel has demonstrated clinical performance and is currently undergoing additional investigation to ensure clinical validation
  • Once approved, could help healthcare professionals to streamline the journey to diagnosis for more patients

Basel, 22 March, 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a collaboration with Eli Lilly and Company to support the development of Roche’s Elecsys® Amyloid Plasma Panel (EAPP). The EAPP is an innovative blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease.

Read more

MHRA to streamline clinical trial approvals in biggest overhaul of trial regulation in 20 years

A series of new measures will be introduced by the Medicines and Healthcare products Regulatory Agency (MHRA) with support from partners to make it faster and easier to gain approval and to run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in over 20 years and will help to make the UK one of the best countries in the world to conduct clinical research for patients and researchers.

Read more

Pfizer Invests $43 Billion to Battle Cancer

  • Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion
  • Proposed combination enhances Pfizer’s position as a leading company in Oncology
  • Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio
  • Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030
  • Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today

NEW YORK & BOTHELL, Wash.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction.

Read more
9 Ways to Become a Better Pharma Recruiter

9 Ways to Become a Better Pharma Recruiter

The pharmaceutical industry is one of the fastest-growing sectors in the world, so it’s no surprise that competition for top talent is fierce. In this article, we’ve outlined 9 ways you can become a better pharma recruiter to improve your hiring success in this challenging job market, from building a strong talent pipeline to leveraging the latest recruitment technologies…

Read more

LEO Pharma and ICON enter a strategic partnership to propel clinical trial execution within medical dermatology

BALLERUP, DENMARK and DUBLIN, IRELAND — 10 March, 2023 — LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

Read more

New organ-on-chip pilot seeks to reduce animal testing in consumer health industry

Basel, Switzerland, March 7, 2023 — A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on-chip” (OoC) technology and interactive computational software. The pilot project, supported by esqLABS, Dynamic42, Placenta Lab of Jena University Hospital, and Bayer’s Consumer Health Division aims to generate clinically relevant data, a key step in evaluating new drug candidates in preclinical research.

Read more